Breaking News

Elan Sells Remaining Alkermes Stake

February 1, 2013

Will no longer own shares of the former EDT business

Elan Corp., through its wholly-owned subsidiary, Elan Science Three Ltd., agreed to sell its remaining 7,750,000 shares of Alkermes plc. The sale is expected to close on February 6, 2013.
In September 2011, Elan’s Drug Technology (EDT) business was combined with Alkermes, and Elan received 31,900,000 shares in the newly created Alkermes. In March 2012, Elan sold 24,150,000 shares of Alkermes in a public offering. After the closing, Elan will no longer own any shares of Alkermes.

Alkermes Contract Pharma Services, part of Alkermes plc, provides product development scale-up and manufacturing services to the pharmaceutical market.

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important